← LLY forward model

LLY · Forward model · Other · Bull case

What has to happen in Other

Model as of

This page changes Other inside the complete LLY model. Every other vertical, corporate programme and valuation assumption stays in the selected portfolio case.

LLY forward model
Horizon
Consolidated fair value $1,170.24 all other verticals held in this portfolio case
Final-quarter revenue $305M 1% of company revenue
Explicit segment contribution $1.78B EBITDA less segment capex, before corporate items

Orforglipron turns the incretin market from an injectable-capacity problem into an oral-scale problem, and retatrutide follows it. Foundayo booked $98 million in its first partial quarter with the prescriber base rising to 36,000, the major ex-US rollout is still ahead in early 2027, and the retatrutide clinical data package is complete with a BLA planned for 2027 Q1. Trend growth runs a point a quarter above base, margin gains 1.5 points on oral manufacturing scale, and the exit multiple holds at 8.5x revenue - still a de-rating from today's 12.9x forward EV/revenue.

Other

Basis quarter$205M
Final quarter$305M
Implied CAGR+8%
Final revenue mix1%

Collaboration, royalty and non-therapeutic revenue. At $205M it is 0.9% of the company and lumpy by construction: it moves when contracts say it does, not when the calendar does, so it is modelled as close to flat.

Last four quarters
2025 Q3 $337M Reported
2025 Q4 $191M Estimated
2026 Q1 $187M Reported
2026 Q2 $205M Reported
collaboration and other revenue
Sequential growth +1.0%/qtr decaying toward +0.5% 1.0% a quarter, well below the 7.9% four-quarter average, because that average is driven by one $337M quarter in 2025 Q3.
Other

Latest: $305M (2031Q2E)

Period Value
2024Q1 $242M
2024Q2 $208M
2024Q3 $263M
2024Q4 $191M
2025Q1 $213M
2025Q2 $202M
2025Q3 $337M
2025Q4 $191M
2026Q1 $187M
2026Q2 $205M
2026Q3E $209M
2026Q4E $213M
2027Q1E $218M
2027Q2E $222M
2027Q3E $226M
2027Q4E $231M
2028Q1E $236M
2028Q2E $240M
2028Q3E $245M
2028Q4E $250M
2029Q1E $255M
2029Q2E $260M
2029Q3E $266M
2029Q4E $271M
2030Q1E $276M
2030Q2E $282M
2030Q3E $288M
2030Q4E $293M
2031Q1E $299M
2031Q2E $305M

Assumptions & reasoning

  • Left ASEASONAL on the brief's own diagnostics: the apparent Q3 factor of 1.33 rests on two observations, $262.8M in 2024 Q3 and $337.2M in 2025 Q3, and the Q1 factor moves 0.104 between the two windows - larger than three of the four factors' deviation from 1.0.
  • The 2024-vintage 10-Q presented a narrower 'Other' line, $50.0M for 2024 Q2 against the restated $207.6M, and only the restated basis makes the five areas sum to reported consolidated revenue. Every figure here is on the restated basis.
LLY model map

Explore another vertical